The worldwide enzyme-linked immunosorbent assay (ELISA) market is projected to grow from USD 2.138 billion in 2022 to USD 3.123 billion in 2029, growing at a CAGR of 5.56%.
Common diagnostic packages of ELISA are HIV disease, pregnancy test, protein detection, etc. The Elisa market is projected to experience robust expansion during the forecast period. This expansion is also attributed to the emerging incidence of infectious and chronic diseases, which require ELISA as an inexpensive diagnostic tool. On the other hand, stringent regulatory requirements, in addition to negative compensation policies regarding ELISA, may reduce the market expansion during certain time periods.
Emerging incidence of infectious diseases is expected to boost the market expansion.
Probably the most prominent factors driving the growth of the market are the increasing incidence of infectious diseases such as HIV, hepatitis, malaria, dengue and influenza among alternative diseases. At the end of 2021, WHO estimated that there were 38.4 million HIV-positive people worldwide, more than two-thirds of whom lived in Africa. WHO also claimed that dengue fever was one of the ten most prevalent diseases in the world. Over the past 50 years, the incidence of dengue has increased by approximately 3000% internationally. WHO also estimates that more than 296 million people worldwide have hepatitis B disease as of 2019.
The demand for forecasting is expected to rise due to the increasing prevalence of infectious diseases. The market growth is expected to be driven by the emerging merits of cutting-edge diagnostic methods to investigate those issues, similar to enzyme-linked immunosorbent assays.
Furthermore, the growing aging society, which is globally susceptible to diseases and chronic illnesses and demands regular diagnostics, is expected to drive the growth of the gasoline market. Compared to younger people, older patients are more likely to have worse disease, according to NCBI (National Center for Biotechnology Data), which published this data in 2021. Thus, it is expected that these factors will significantly increase the expansion of the market. By increasing the demand for enzyme-linked immunosorbent assay.
The disorder diagnostics segment is expected to drive market expansion.
Due to the increasing merit of enzyme-linked immunosorbent assay tests for the diagnosis of specific antigens, a large share of the disorder diagnosis market is predicted. In 2022, WHO estimated that non-communicable diseases would cause approximately 41 million deaths, equivalent to 71% of all deaths worldwide. Due to these incidents, there is now a greater need for environmentally friendly diagnostic methods such as ELISA for detection as suggested to reduce the incidence of mortality.
Furthermore, according to the International Cancer Observatory, there were approximately 19.3 million undiagnosed cancer cases and approximately 10.0 million cancer deaths worldwide in 2020. Since the ELISA is an invaluable tool for assessing antigens, stands call for its use throughout the world in the event of cancer.
According to a 2020 Nature Medical study, the enzyme-linked immunosorbent assay may be outdated for detecting both breast cancer antigen and prostate cancer antigen. Such accurate antigen screening and cost-effective diagnostics are expected to increase the demand for ELISA and fuel the market growth during the analysis period.
North America is expected to maintain a significant share in the market
Due to the rapid creation of technological advancements in screening devices such as Elisa, the US is more likely to dominate the worldwide market. The increasing incidence of certain infectious and chronic diseases in this demographic is contributing to the strong demand for enzyme-linked immunosorbent assay. For example, the CDC (Centers for Disease Control and Prevention) reported in 2022 that more than 60% of American citizens had at least one energy disorder similar to cancer, heart disease or stroke.
The market is expected to grow on this patch due to emerging R&D expenditure in addition to various investment projects for diagnostics. According to the 2020 Binder Dijker Otte USA report, companies listed in the biotechnology index increased their R&D spending by nearly 16% in 2020 to US$284.25 million in the United States.
Main characteristics:
| document components | main points |
| refuse. of pages | 135 |
| forecast length | 2022 – 2029 |
| Estimated market value in 2022 (USD). | $2.14 billion |
| Estimated Marketplace Worth (USD) by 2029. | $3.12 billion |
| Compound Annual Increase Fee | 5.5% |
| coated area | international |
Aggressive orders and research
- Main Hobby Gamers and Tech Research
- market ratio research
- Mergers, Acquisitions, Pledges, and Collaborations
- Offensive Dashboard
Corporate Profile
- Pestka Biomedical Laboratories, Inc.
- Diaclone SAS
- Thermo Fisher Medical Inc.
- Azure Biosystems Inc.
- Research & Development Technology, Inc.
- Rebiotech, Inc.
- alabscience
- BioLegend, Inc.
- randox toxicology
- StemCell Applied Sciences Inc.
- Genway Biotech, Inc.
Division:
sort through
- oblique elisa
- Sandwich Elisa
- aggressive alyssa
through software
- food and beverages
- vaccine building
- immunology
- diagnosis of disease
- drug tracking
- Other
through Finnish customers
- pharmaceutical industry
- Hospitals and Clinics
- diagnostic center
- Other
through geography
- Answer we
- United States of america
- Canada
- Mexico
- south we
- brazil
- argentina
- Other
- Europe
- UK
- Germany
- France
- Italy
- spain
- Other
- Heart East and Africa (MEA)
- Saudi Arab
- United Arab Emirates
- israel
- Other
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Indonesia
- Thailand
- taiwan
- Other
For more information about this file discuss https://www.researchandmarkets.com/r/l0b33j
About ResearchandMarkets.com
ResearchAndMarkets.com is the region’s leading source for global market analysis stories and market intelligence. We provide you with unedited knowledge on world and regional markets, leading industries, leading corporations, untouched merchandise and unedited features.
-
International Enzyme-Connected Immunosorbent Assay (ELISA) Market